SAB Biotherapeutics, Inc. Common Stock (SABS)
SAB Biotherapeutics, Inc. (SABS) is a biotechnology company specializing in developing and manufacturing innovative antibody-based therapeutics. The company leverages its proprietary platform to produce fully-human, polyclonal antibodies derived from transchromosomic cattle, aimed at treating infectious diseases and providing immune protection. SAB Biotherapeutics focuses on rapid response to emerging health threats and enhancing immune treatments through its advanced biopharmaceutical technologies.
Company News
SILQFi has launched Omni, a new financial platform for small businesses, after acquiring OXO. The platform integrates point-of-sale, procurement, payments, and credit access to streamline merchant workflows and improve capital access in Saudi Arabia.
SAB BIO, a clinical-stage biopharmaceutical company, reported financial results for Q1 2025. The company made progress on its type 1 diabetes program, including positive Phase 1 data for its lead candidate SAB-142. SAB BIO also achieved manufacturing milestones and saw a decrease in R&D and G&A expenses.
SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.